OBJECTIVE: The ligand EphrinB2 and the corresponding receptor EphB4 are up-regulated and involved in tumour growth in various human cancers. However, little is known about how this receptor-ligand complex contributes to the progression of glioma. This prompted us to study the association between the expressions of EphrinB2 and EphB4, clinicopathological variables, and glioma patient outcome. METHODS: Immunohistochemical staining was performed to detect the expression patterns of EphrinB2 and EphB4 in the biopsies from 96 patients with primary gliomas. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. RESULTS: Immunohistochemical analysis revealed that the expression of EphrinB2 was significantly correlated with that of EphB4 (r=0.86, p=0.002). EphrinB2 and EphB4 were significantly associated with the Karnofsky performance scale (KPS) score and World Health Organization grades of patients with gliomas, respectively. Especially, the positive expression rates of EphrinB2 and EphB4 were significantly higher in patients with higher grade (both p=0.001) and lower KPS score (p=0.002 and 0.003, respectively). Multivariate Cox regression analysis revealed that EphrinB2 and EphB4 expressions were both independent prognostic factors for progress-free survival of glioblastoma patients (both p=0.02). CONCLUSION: Our data indicated for the first time that EphrinB2 and EphB4 expressions increase according to the histopathological grade and KPS score of glioma, and their expression levels are related to the progression-free survival of glioblastoma patients.
OBJECTIVE: The ligand EphrinB2 and the corresponding receptor EphB4 are up-regulated and involved in tumour growth in various humancancers. However, little is known about how this receptor-ligand complex contributes to the progression of glioma. This prompted us to study the association between the expressions of EphrinB2 and EphB4, clinicopathological variables, and gliomapatient outcome. METHODS: Immunohistochemical staining was performed to detect the expression patterns of EphrinB2 and EphB4 in the biopsies from 96 patients with primary gliomas. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. RESULTS: Immunohistochemical analysis revealed that the expression of EphrinB2 was significantly correlated with that of EphB4 (r=0.86, p=0.002). EphrinB2 and EphB4 were significantly associated with the Karnofsky performance scale (KPS) score and World Health Organization grades of patients with gliomas, respectively. Especially, the positive expression rates of EphrinB2 and EphB4 were significantly higher in patients with higher grade (both p=0.001) and lower KPS score (p=0.002 and 0.003, respectively). Multivariate Cox regression analysis revealed that EphrinB2 and EphB4 expressions were both independent prognostic factors for progress-free survival of glioblastomapatients (both p=0.02). CONCLUSION: Our data indicated for the first time that EphrinB2 and EphB4 expressions increase according to the histopathological grade and KPS score of glioma, and their expression levels are related to the progression-free survival of glioblastomapatients.
Authors: S Ram Kumar; Jasbir Singh; Guangbin Xia; Valery Krasnoperov; Loubna Hassanieh; Eric J Ley; Jeffrey Scehnet; Neil G Kumar; Debra Hawes; Michael F Press; Fred A Weaver; Parkash S Gill Journal: Am J Pathol Date: 2006-07 Impact factor: 4.307
Authors: Guangbin Xia; S Ram Kumar; Rizwan Masood; Sutao Zhu; Ramchandra Reddy; Valery Krasnoperov; David I Quinn; Susan M Henshall; Robert L Sutherland; Jacek K Pinski; Siamak Daneshmand; Maurizio Buscarini; John P Stein; Chen Zhong; Daniel Broek; Pradip Roy-Burman; Parkash S Gill Journal: Cancer Res Date: 2005-06-01 Impact factor: 12.701
Authors: Rizwan Masood; S Ram Kumar; Uttam K Sinha; David L Crowe; Valery Krasnoperov; Ramachandra K Reddy; Sergey Zozulya; Jasbir Singh; Guangbin Xia; Daniel Broek; Axel H Schönthal; Parkash S Gill Journal: Int J Cancer Date: 2006-09-15 Impact factor: 7.396
Authors: Georg Martiny-Baron; Philipp Holzer; Eric Billy; Christian Schnell; Joseph Brueggen; Mireille Ferretti; Niko Schmiedeberg; Jeanette M Wood; Pascal Furet; Patricia Imbach Journal: Angiogenesis Date: 2010-08-29 Impact factor: 9.596
Authors: Nicole K Noren; Mark Lu; Andrew L Freeman; Mitchell Koolpe; Elena B Pasquale Journal: Proc Natl Acad Sci U S A Date: 2004-04-05 Impact factor: 11.205
Authors: Jamie L McCall; Drew Gehring; Beth K Clymer; Kurt W Fisher; Binita Das; David L Kelly; Hyunseok Kim; Michael A White; Robert E Lewis Journal: Mol Cell Biol Date: 2016-08-12 Impact factor: 4.272
Authors: Shilpa Bhatia; Sanjana Bukkapatnam; Benjamin Van Court; Andy Phan; Ayman Oweida; Jacob Gadwa; Adam C Mueller; Miles Piper; Laurel Darragh; Diemmy Nguyen; Ahmed Gilani; Michael Knitz; Thomas Bickett; Adam Green; Sujatha Venkataraman; Rajeev Vibhakar; Diana Cittelly; Sana D Karam Journal: Mol Carcinog Date: 2020-06-22 Impact factor: 4.784
Authors: K R Kampen; F J G Scherpen; G Garcia-Manero; H Yang; G J L Kaspers; J Cloos; C M Zwaan; M M van den Heuvel-Eibrink; S M Kornblau; E S J M De Bont Journal: Mol Cancer Res Date: 2015-05-05 Impact factor: 5.852
Authors: C Depner; H Zum Buttel; N Böğürcü; A M Cuesta; M R Aburto; S Seidel; F Finkelmeier; F Foss; J Hofmann; K Kaulich; S Barbus; M Segarra; G Reifenberger; B K Garvalov; T Acker; A Acker-Palmer Journal: Nat Commun Date: 2016-07-29 Impact factor: 14.919
Authors: Ann Bohannon-Stewart; Gary Kelley; Boniface Kimathi; Sri Harsha K V Subramanya; Joseph Donkor; Carl Darris; James Tyus; Ashley Payne; Shannon Byers; Dafeng Hui; Samuel Nahashon; Fur-Chi Chen; Michael Ivy; Xiaofei Wang Journal: Genet Res Int Date: 2014-01-16